摘要
目的探讨曲美他嗪(TMZ)在不同病因所致左室射血分数降低慢性心力衰竭(HF-REF)中的应用效果。方法回顾性分析某院HF-REF患者263例,按照心力衰竭病因的不同将患者分为冠心病组、高血压性心脏病组、瓣膜性心脏病组和扩张型心肌病组,同时根据每组是否应用TMZ又分为TMZ亚组和非TMZ亚组,评估TMZ在其中的治疗效果。结果各组中治疗后TMZ亚组LVEF、6-MWD及NT-proBNP水平均优于非TMZ亚组,两者分别比较差异具有统计学意义(P<0.05)。冠心病组LVEF、6-MWD及NT-proBNP治疗后改善幅度[△值分别为(6.84±2.28)%、(126.46±7.43)m、(243.42±25.42)pg/L)]明显优于瓣膜性心脏病组、高血压性心脏病组及扩张型心肌病组,两者分别比较差异具有统计学意义(P<0.05)。结论 TMZ能明显提高冠心病所致HF-R EF患者的心功能,也可使高血压性心脏病、瓣膜性心脏病和扩张型心肌病所致HF-R EF患者获益。
Objective To explore the effect of trimetazidine(TMZ) in the treatment of left ventricular ejection fraction induced chronic heart failure(HF-REF) caused by different reasons.Me thods 263 patients with HF-REF in a hospital were retrospectively analysed.In accordance with the causes of heart failure,they were divided into coronary heart disease group,hypertensive heart disease group,valvular heart disease group and expanded cardiomyopathy group.In accordance with their taking of TMZ or not,these groups were further divided into TMZ subgroups and non-TMZ subgroups to evaluate the effect of TMZ.Re s ults After treatment,the levels of LVEF,6-MWD and NT-pro BNP of TMZ subgroups were better than those of non-TMZ subgroups and the differences showed statistical significance(P <0.05).After treatment,increase values △of LVEF,6-MWD and NT-pro BNP in the coronary heart disease group [△ =(6.84 ±2.28)%,(126.46 ±7.43)m,(243.42 ±25.42)pg/L] were significantly better than those of hypertensive heart disease group,valvular heart disease group and expanded cardiomyopathy group and the differences were statistically significant( P <0.05).Conclus ion TMZ could effectively improve cardiac function of HF-REF patients caused by coronary heart disease and benefit HF-REF patients caused by hypertensive heart disease,valvular heart disease and expanded cardiomyopathy.
出处
《中国疗养医学》
2018年第2期128-130,共3页
Chinese Journal of Convalescent Medicine
关键词
曲美他嗪
左室射血分数
慢性心力衰竭
冠心病
高血压性心脏病
瓣膜性心脏病
扩张型心肌病
Trimetazidine
Left ventricular ejectionfraction
Chronic heart failure
Coronary heart disease
Hypertensive heart disease
Valvular heart disease
Expanded cardiomyopathy
